Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 2068Radiotherapy 1990Cisplatin 1857Carboplatin 1560Gemcitabine 1455Paclitaxel 1322Bevacizumab 1321pembrolizumab 1240Docetaxel 1227Oxaliplatin 1184Capecitabine 1179Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 973Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 641Lenalidomide 619Biopsy 595Specimen Handling 570

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × small molecule inhibitor THX-B × Clear all
NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡